Pharmaceutical nanotechnology experts are specialized scientists and researchers who focus on applying nanotechnology principles to the field of drug development and delivery. These experts leverage the unique properties of materials at the nanoscale—typically between 1 to 100 nanometers—to create innovative drug formulations that improve therapeutic efficacy, targeting, and patient compliance. Their work often involves designing nanoparticles, liposomes, nanoemulsions, and other nanocarriers that can enhance drug solubility, stability, and controlled release. By manipulating materials at such a minute scale, pharmaceutical nanotechnology experts enable drugs to cross biological barriers more effectively, reduce side effects by targeting specific tissues or cells, and develop novel treatment options for complex diseases such as cancer, neurological disorders, and infectious diseases.
The role of pharmaceutical nanotechnology experts extends beyond formulation development; they are also deeply involved in characterizing nanomaterials, assessing their safety and biocompatibility, and navigating regulatory pathways for novel nanomedicines. Their expertise requires interdisciplinary knowledge in pharmaceutics, materials science, molecular biology, and toxicology. As nanotechnology continues to revolutionize the pharmaceutical industry, these professionals play a crucial role in translating laboratory discoveries into clinically viable therapies. Their contributions not only pave the way for personalized medicine but also improve drug delivery efficiency, minimize toxicity, and ultimately enhance patient outcomes in modern healthcare.
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami, United States
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N D Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : R&D consultancy at the medicines discovery catapult: De-risking drug discovery for innovators
Adriana Gambardella, Medicine Discovery Catapult, United Kingdom
Title : Biocompatible synthesis of non crystalline iron oxide nanoparticles with stable colloidal properties
Lan Wang, Paretor LLC, United States
Title : Hydrogen sulfide in sepsis: From bench to bedside
Madhav Bhatia, University of Otago, New Zealand
Title : Biocompatibility and subcutaneous host response to silk fibroin–chitosan composite plugs: Progress toward biodegradable implant materials
Luis Jesus Villarreal Gomez, Universidad Autónoma de Baja California, Mexico